Financial Performance Summary - The company achieved operating revenue of 193.05 million yuan, representing a year-on-year increase of 53.36% [3] - The total profit was -107.32 million yuan, with a net profit attributable to the parent company of -103.28 million yuan, and a net profit excluding non-recurring gains and losses of -134.82 million yuan, all showing a reduction in losses compared to the previous year [3] - The total assets at the end of the reporting period were 1.51 billion yuan, a decrease of 6.65% from the beginning of the period, while the equity attributable to the parent company was 1.36 billion yuan, down 7.54% [4] Business Operations and Factors Influencing Performance - The company focused on consolidating existing businesses while actively exploring new ones, with rapid growth in technology service businesses such as gene sequencing and gene synthesis driving revenue growth [5] - The company improved operational efficiency, controlling expenses effectively despite significant revenue growth, and reduced R&D expenses by optimizing resource allocation and focusing on advantageous projects [5] Changes in Key Financial Metrics - The company experienced a significant reduction in operating profit and total profit compared to the previous year, primarily due to increased revenue from new technology services and effective expense management [6]

Core Viewpoint - Kangwei Century (688426.SH) reported a significant increase in revenue for the year 2025, driven by growth in technology services such as gene sequencing and synthesis, despite facing intense market competition [1] Financial Performance - The company achieved operating revenue of 193.05 million yuan, representing a year-on-year increase of 53.36% [1] - The net profit attributable to the parent company was -103.28 million yuan, while the net profit after deducting non-recurring gains and losses was -134.82 million yuan, both showing a reduction in losses compared to the previous year [1] Business Strategy - The management focused on consolidating existing businesses while actively exploring new opportunities, contributing to the revenue growth [1] - The company improved operational efficiency, controlling expenses effectively despite significant revenue growth [1] Research and Development - R&D expenditures decreased year-on-year as the company optimized resource allocation and focused on advantageous projects to enhance R&D efficiency [1]

Core Viewpoint - The company 康为世纪 (688426.SH) expects to reduce its net loss for the year 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -1.12 billion to -914.41 million, reflecting a year-on-year reduction in loss of 28.91% to 41.83% [1] Financial Performance - The projected net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to range from -1.43 billion to -1.23 billion, indicating a year-on-year reduction in loss of 20.64% to 31.90% [1] - The main reason for the performance change is attributed to the recovery phase of the life sciences and diagnostic reagent industry, along with the ongoing market expansion of new businesses that have not yet achieved economies of scale [1] Revenue Growth - The reduction in net loss is primarily due to an increase in main business revenue, with significant overall sales revenue growth during the reporting period [1] - The growth is mainly driven by the rapid expansion of the company's technology service businesses, including gene sequencing and gene synthesis [1]

Core Viewpoint - The company 康为世纪 (688426.SH) expects to reduce its net loss for the year 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -1.12 billion to -914.41 million, reflecting a year-on-year reduction in loss of 28.91% to 41.83 [1] Financial Performance - The projected net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to range from -1.43 billion to -1.23 billion, indicating a year-on-year reduction in loss of 20.64% to 31.90% [1] - The main reason for the change in performance is attributed to the recovery phase of the life sciences and diagnostic reagent industry, along with the ongoing market expansion of new business which has not yet achieved economies of scale [1] Revenue Growth - The reduction in net loss is primarily due to an increase in main business revenue, with significant overall sales revenue growth during the reporting period [1] - The growth is mainly driven by the rapid expansion of the company's technology service businesses, including gene sequencing and gene synthesis [1]